Aimed at ensuring patient safety and minimizing further stress to the healthcare system, Eli Lilly (NYSE:LLY) has suspended enrollment
in most of its clinical trials and has delayed the start of most new
studies. It does not expect adjustments to its previously announced
timelines for ongoing Phase 3 trials with the exception of mirikizumab
for gastrointestinal indications.
At this snapshot in time, it does not expect to change its 2020 guidance.
https://seekingalpha.com/news/3554088-lilly-pauses-enrollment-in-clinical-trials-amid-coronavirus-outbreak
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.